ZURICH, Aug 27 (Reuters) - Swiss-listed drugmaker Cassiopea SKIN.S said on Thursday it won approval for its first medicine, an acne treatment called Winlevi, from the U.S. Food and Drug Administration, setting the stage for a likely capital increase to support the launch.
Prescription treatment Winlevi, also known generically as clascoterone, won approval for patients 12 years and older, Cassiopea said in a statement. It is a topical medicine aimed at inhibiting hormones, called androgens, thought to play a role in acne lesions in men and women.
(Reporting by Silke Koltrowitz and John Miller; editing by Thomas Seythal)
((email@example.com; +41 41 528 3638;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.